Bay State Times
SEE OTHER BRANDS

The latest news from Massachusetts

Bay State Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.

Press releases published on May 21, 2025

Cangrade Launches Newly Patented Resume Ranker, Enabling Recruiters to Uncover High-Fit Candidates Quickly and Accurately

Cangrade Launches Newly Patented Resume Ranker, Enabling Recruiters to Uncover High-Fit Candidates Quickly and Accurately

WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Cangrade today announced the launch of its newly patented Resume Ranker (U.S. Patent No. 12,287,833), an AI feature that enables recruiters to quickly and effectively narrow down high-fit candidates from …

Flywire Surpasses $320 Million in Past-Due Tuition Collected and 161,000+ Student Enrollments Saved at U.S. Higher Education Institutions

Flywire Surpasses $320 Million in Past-Due Tuition Collected and 161,000+ Student Enrollments Saved at U.S. Higher Education Institutions

Flywire’s Student Financial Software helps U.S. institutions boost enrollment and accelerate cash flow Automated payment innovation fuels accelerated adoption of Flywire's Third-Party Invoicing and 529 Disbursement solutions BOSTON, May 21, 2025 (GLOBE …

ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize time-to-delay of levodopa/carbidopa initiation as an endpoint to measure trial success, which Company believes is a direct measure of …

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important …

SparkCharge Raises $30.5 Million in Capital to Accelerate Mobile EV Charging Expansion

SparkCharge Raises $30.5 Million in Capital to Accelerate Mobile EV Charging Expansion

SOMERVILLE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- SparkCharge, the world’s largest off-grid electric vehicle fleet charging network and creator of the first mobile, off-grid EV charger, today announced the close of a $15.5 million Series A-1 funding …

Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025

Rectify Pharma to Present Translational Data on Novel Approach to Treat Chronic Kidney Disease and Vascular Calcification at ERA 2025

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today announced that it will present a …

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Host 2025 Investor and Analyst Day

BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or …

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service